CHO Pharma, Inc. (TPEX:6586)

Market Cap	7.98B
Revenue (ttm)	3.21M
Net Income (ttm)	-230.38M
Shares Out	214.01M
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152,266
Average Volume	267,531
Open	37.55
Previous Close	37.85
Day's Range	36.85 - 38.10
52-Week Range	35.75 - 68.80
Beta	-0.53
RSI	31.58
Earnings Date	Aug 7, 2025

About CHO Pharma

CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6586